Zolgensma was developed by AveXis, a biotechnology company acquired by Novartis for $8.7 billion in 2018.
AveXis is negotiating with governments and reimbursement agencies to decide on terms of the “Day One” access program, which would provide rapid access in all countries in the European Union.
In May 2019, the FDA approved Zolgensma for infants under the age of 2, with the drug totalling $361 million in sales last year.
Zolgensma recently gained approval in Japan. Novartis expects decisions to be made by Swiss, Canadian and Australian authorities in late 2020 or early 2021.
More articles on biologics:
28.4M elective surgeries could be canceled in 2020 — orthopedic procedures hit hardest
Research finds lowest average cost of hip, knee replacements at 3 New York City hospitals
Texas orthopedic group snares 2 paycheck protection program loans
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
